Senators Urge CFIUS Review of UAE Investment in Trump-Linked Crypto Firm World Liberty Financial 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
Anduril Eyes $60 Billion Valuation in New Funding Round to Expand Defense Manufacturing and Autonomous Fighter Jet Development 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
Valero Energy Expands Venezuelan Crude Imports as U.S. Sanctions Ease 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Grok AI Market Share Surges as xAI Faces Scrutiny Over Image Generation Controversy 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Paramount Skydance Appoints Rene Augustine as SVP of Global Public Policy Amid Warner Bros Takeover Battle 
Lockheed Martin Secures $101M in U.S. Defense Contracts for AEGIS, F-35, and Missile Systems 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
CARLSBAD, Calif., April 17, 2018 -- GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its first quarter earnings results after market close on Tuesday, May 1, 2018. Management will hold a conference call to review the Company's financial performance starting at 4:30 p.m. ET on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the GenMark Diagnostics, Inc. website at www.genmarkdx.com under the investor relations section and will be archived for future reference. To listen to the conference call, please dial (877) 312-5847 (US/Canada) or (253) 237-1154 (International) and use the conference ID number 9384229 approximately five minutes prior to the start time.
ABOUT GENMARK DIAGNOSTICS
GenMark Diagnostics (NASDAQ: GNMK) is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care. Utilizing GenMark's proprietary eSensor® detection technology, GenMark's eSensor XT-8® and ePlex® systems are designed to support a broad range of molecular diagnostic tests with compact, easy-to-use workstations and self-contained, disposable test cartridges. GenMark’s ePlex: The True Sample-to-Answer Solution™ is designed to optimize laboratory efficiency and address a broad range of infectious disease testing needs, including respiratory, bloodstream, and gastrointestinal infections. For more information, visit www.genmarkdx.com.
Investor Relations Contact
Lynn Pieper Lewis or Leigh Salvo
(415) 937-5404
[email protected]
